This is a review by Li, Walker and De Oliviera: "Vancomycin Resistance in Enterococcus and Staphylococcus aureus". Mark Walker was one of the inventors of the PBT2 patent. This is a huge review with over 600 references.
There is one chapter about PBT2: Reversing Antibiotic Resistance.
In this chapter they tell: "Bohlmann et al. showed that PBT2, in the presence of zinc, is bactericidal against MRSA and VRE. In addition, it also reverses acquired bacterial resistance to many clinical antibiotics including vancomycin at sub-inhibitory concentrations. The combination of PBT2 + zinc + vancomycin also significantly reduced VRE infection in a murine wound infection model. The authors were unable to select for mutants resistant to PBT2 + zinc treatment [601]. PBT2 and zinc was also able to break intrinsic polymyxin resistance in MRSA and VRE in vitro as demonstrated by De Oliveira et al. [603], highlighting the utility of PBT2 to reverse both intrinsic and acquired mechanisms of antibiotic resistance in bacteria".
ATH Price at posting:
1.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)